Kyowa Hakko Kirin (4151)

Executive Summary

Kyowa Kirin is a Japanese biopharmaceutical company focused on innovative antibody-based therapies for oncology, kidney disease, and immunology. With approved products like Mogamulizumab (Poteligeo®) for cutaneous T-cell lymphoma and Burosumab (Crysvita®) for X-linked hypophosphatemia, the company has a strong commercial base. Its pipeline includes next-generation antibodies such as the anti-OX40 monoclonal antibody KHK4083 (amlitelimab) in Phase 3 for atopic dermatitis and bispecific T-cell engagers for solid tumors. Upcoming catalysts include pivotal clinical data and regulatory decisions that could drive near-term growth. The company's strategic emphasis on differentiated biologics positions it well for expansion in targeted therapies.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 top-line results for KHK4083 (amlitelimab) in moderate-to-severe atopic dermatitis60% success
• Q4 2026FDA decision on supplemental BLA for Mogamulizumab in combination with chemotherapy for adult T-cell leukemia-lymphoma55% success
• Q2 2026Initiation of Phase 2 study for bispecific antibody targeting CLEC12A in acute myeloid leukemia70% success